Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613359 | 0.82 | ACHE (0.50) | ACHECYP1A2CYP2A6CRHBPCRHR2 | |
| SCHEMBL12160924 | 0.80 | ACHE (1.00) | ACHECYP1A2CYP2A6CRHBPCRHR2 | |
| SCHEMBL23453280 | 0.78 | KDM4E (0.59) | ACHEKDM4EMAPTSMN1; SMN2TDP1 | |
| SCHEMBL5912659 | 0.78 | ACHE (0.41) | ACHECYP1A2KDM4ELMNAGAA | |
| SCHEMBL5894550 | 0.78 | ACHE (0.47) | ACHECYP1A2CYP2A6CRHBPCRHR2 | |
| SCHEMBL23412344 | 0.78 | ACHE (0.42) | ACHECRHBPCRHR2KEAP1NFE2L2 | |
| SCHEMBL11818882 | 0.77 | ACHE (0.46) | ACHECYP1A2CYP2A6CRHBPCRHR2 | |
| SCHEMBL8745747 | 0.77 | ACHE (0.41) | ACHE | |
| SCHEMBL3738777 | 0.76 | ACHE (0.42) | ACHEKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL22034130 | 0.76 | ACHE (0.68) | ACHECYP1A2CYP2A6KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197046-B | Halogenation method of unsaturated hydrocarbon | 华南理工大学 | 2023-12-15 | — | — | CN | claimed |
| CN-117384154-A | Pyrroloquinolinone compound, synthesis method and application thereof | 广州医科大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-115197046-B | Halogenation method of unsaturated hydrocarbon | 华南理工大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-115197046-A | Halogenation method of unsaturated hydrocarbon | 华南理工大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-110256411-B | Preparation method of 2, 3-disubstituted benzo-gamma-pyrone derivative | 华侨大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-108794395-B | Preparation method of 2-quinolinone compounds | 大连理工大学 | 2021-04-20 | — | — | CN | disclosed |
| CN-110256411-A | A kind of 2,3- disubstituted benzenes simultaneously-preparation method of gamma-pyrone derivative | 华侨大学 | 2019-09-20 | — | — | CN | disclosed |
| CN-108794395-A | A kind of preparation method of 2- quinolinones compounds | 大连理工大学 | 2018-11-13 | — | — | CN | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| EP-1313707-A1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002094268-A1 | TETRAHYDROQUINOLIN DERIVATIVES FOR THE INHIBITION OF DISEASES ASSOCIATED WITH ESTROGEN DEPRIVATION OR WITH AN ABERRANT PHYSIOLOGICAL RESPONSE TO ENDOGENOUS ESTROGEN | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094788-A1 | 2-SUBSTITUTED 1,2,3,4-TETRAHYDROQUINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | PHARMACIA CORPORATION | 2002-06-13 | — | — | US | disclosed |
| WO-2002018377-A1 | COMPOUNDS CONTAINING A BICYCLIC RING SYSTEM USEFUL AS ALPHA V BETA 3 ANTAGONISTS | PHARMACIA CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
| US-6183934-B1 | FOE USE IN FORMATION OF PATTERN OF INSULATION FILM, PASSIVATION FILM, .ALPHA.-RAY SHIELDING FILM, OPTICAL WAVEGUIDE | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-1051413-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999037635-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | ACHE 1430/4885CYP1A2 110/4885CYP2A6 358/4885 |
| US-20020072518-A1 | For therapy tumor metastasis, tumor growth, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atheroscelorosis, macular degeneration, retinopathy | ITGB1, ITGB5, ITGB3 | ACHE 4254/4885CYP1A2 4692/4885CYP2A6 3687/4885 |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | ACHE 371/4885CYP1A2 38/4885CYP2A6 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.